Heron Therapeutics
HRTX
69 hedge funds and large institutions have $327M invested in Heron Therapeutics in 2014 Q2 according to their latest regulatory filings, with 36 funds opening new positions, 19 increasing their positions, 10 reducing their positions, and 7 closing their positions.
414% more first-time investments, than exits
New positions opened: 36 | Existing positions closed: 7
90% more repeat investments, than reductions
Existing positions increased: 19 | Existing positions reduced: 10
73% more funds holding
Funds holding: 40 → 69 (+29)
13% more capital invested
Capital invested by funds: $289M → $327M (+$37.9M)
33% less funds holding in top 10
Funds holding in top 10: 6 → 4 (-2)
100% less call options, than puts
Call options by funds: $0 | Put options by funds: $12K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
+$8.36M |
| 2 |
BC
Broadfin Capital
New York
|
+$6.87M |
| 3 |
TCM
Tang Capital Management
San Diego,
California
|
+$6.1M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$5.82M |
| 5 |
BFA
BlackRock Fund Advisors
San Francisco,
California
|
+$5.71M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ICM
ISZO Capital Management
New York
|
-$4.83M |
| 2 |
AC
Ascend Capital
Orinda,
California
|
-$1.75M |
| 3 |
DCM
Driehaus Capital Management
Chicago,
Illinois
|
-$1.73M |
| 4 |
PA
Perceptive Advisors
New York
|
-$1.53M |
| 5 |
Morgan Stanley
New York
|
-$1.31M |
HRTX Hedge Fund Activity: Q2 2014 in Review
69 of the 3,479 institutional investors tracked by Wall St. Rank reported a position in Heron Therapeutics (HRTX) for Q2 2014, worth a combined $327M — up 13% from $289M a quarter earlier.
Buyers outnumbered sellers: 36 funds opened new HRTX positions and 7 closed out — a net gain of 29 holders — while 19 added to existing stakes and 10 trimmed.
The largest buyer was Cormorant Asset Management, opening a new position worth an estimated $8.36M. The largest seller was ISZO Capital Management, exiting entirely with an estimated $4.83M sold.
- 69 institutional investors held Heron Therapeutics (HRTX) as of Q2 2014, up from 40 in Q1 2014.
- Funds reported $327M of Heron Therapeutics stock for Q2 2014, up 13% quarter-over-quarter.
- 36 funds opened new Heron Therapeutics positions in Q2 2014 and 7 closed out, a net change of +29 holders.
- The largest Heron Therapeutics buyer in Q2 2014 was Cormorant Asset Management, an estimated $8.36M added.
- The largest Heron Therapeutics seller in Q2 2014 was ISZO Capital Management, an estimated $4.83M sold.
Based on aggregated 13F filings for Q2 2014.